The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

The Johns Hopkins T-cell and Cutaneous Lymphoma Program provides expertise in all forms of systemic peripheral T-cell lymphomas and cutaneous T-cell lymphomas, including mycosis fungoides and others.

Distinguishing TMM from primary cutaneous neoplasms may be challenging and is often dependent on the identification of an adjacent conventional melanoma. In particularly difficult cases, molecular ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell ... in the primary endpoint of complete renal response, subsequent analyses suggested that the ...

This study focused solely on booster vaccinations and did not evaluate the safety of the primary MMR series ... Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children ...